MCF Advisors’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-16
Closed -$2.76K 1417
2026
Q1
$2.76K Hold
16
﹤0.01% 1163
2025
Q4
$3.19K Buy
+16
New +$2.9K ﹤0.01% 1011
2019
Q2
Sell
-25
Closed -$4K 448
2019
Q1
$4K Buy
25
+5
+25% +$657 ﹤0.01% 387
2018
Q4
$2K Sell
20
-8
-29% -$1K ﹤0.01% 443
2018
Q3
$4K Buy
+28
New +$3.46K ﹤0.01% 402

Other funds holding CRL

MCF Advisors's CRL Position: Q2 2026 in Review

MCF Advisors sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 16 shares — an estimated $2.76K sold.

MCF Advisors first reported a position in CRL in Q3 2018 and held it in 5 quarters. The position peaked at $4K in Q1 2019. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • MCF Advisors reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • MCF Advisors sold 16 Charles River Laboratories shares in Q2 2026, an estimated $2.76K.
  • MCF Advisors first reported a position in Charles River Laboratories in Q3 2018 and held it in 5 quarters.
  • MCF Advisors's Charles River Laboratories position peaked at $4K in Q1 2019.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.